Compare ANL & PMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | PMT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.8M | 812.7M |
| IPO Year | 2022 | 2009 |
| Metric | ANL | PMT |
|---|---|---|
| Price | $10.62 | $7.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $29.50 | $10.61 |
| AVG Volume (30 Days) | 319.9K | ★ 2.6M |
| Earning Date | 08-14-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 22.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $351,067,000.00 |
| Revenue This Year | $243.83 | N/A |
| Revenue Next Year | N/A | $11.87 |
| P/E Ratio | ★ N/A | $17.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $6.70 |
| 52 Week High | $17.25 | $13.80 |
| Indicator | ANL | PMT |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 33.89 |
| Support Level | $8.96 | $6.70 |
| Resistance Level | $12.49 | $9.80 |
| Average True Range (ATR) | 1.30 | 0.23 |
| MACD | -0.29 | 0.04 |
| Stochastic Oscillator | 5.98 | 28.13 |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.